Cover Image
市場調查報告書

癌症免疫療法的全球市場 2022年為止的預測:種類 (單株抗體 (非修飾,結合),癌症疫苗,免疫查核點抑制劑 (PD-1,PD-L1,CTLA-4)·各用途 (肺癌),黑色素瘤,淋巴瘤,白血病)

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 423698
出版日期 內容資訊 英文 230 Pages
訂單完成後即時交付
價格
Back to Top
癌症免疫療法的全球市場 2022年為止的預測:種類 (單株抗體 (非修飾,結合),癌症疫苗,免疫查核點抑制劑 (PD-1,PD-L1,CTLA-4)·各用途 (肺癌),黑色素瘤,淋巴瘤,白血病) Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022
出版日期: 2018年04月02日 內容資訊: 英文 230 Pages
簡介

本報告提供全球癌症免疫療法的市場相關分析,提供疾病概要和主要的治療選擇,整體市場規模趨勢預測 (今後5∼10年份),各級產品·不同症狀·地區別的詳細趨勢,主要的開發中產品 (臨床實驗中的產品)的概要,企業間競爭·資本交易的動向,主要企業簡介·市場佔有率等訊。

第1章 分析師分析

第2章 分析方法

第3章 癌症免疫療法:概要

第4章 市場推動因素與課題

  • 推動因素
    • 癌症患者的增加
    • 查核點抑制劑的銷售額,促進市場成長
    • 老年人口的增加
    • 先進國家市場的巨額醫療費用支出
    • 強力的開發中產品
    • 改善各種症狀的有效性
    • 癌症免疫療法產品的認證量·攝取量的增加
  • 課題
    • 主力醫藥品的專利到期
    • 伴隨副作用的增加,配合免疫療法的動向
    • 癌症免疫療法的開發費:可說是天價般昂貴
    • 治療費高
    • 知名度低
  • 市場機會
    • Opdivo和Keytruda:大幅成長的機會
    • 透過聯合治療,大幅提升存活率的可能性
    • CAR-T療法:未來的癌症治療
    • 下一代型免疫療法:小規模企業提供巨大的市場機會

第5章 全球癌症免疫療法市場未來展望

第6章 全球癌症免疫療法市場:各級產品

  • 單株抗體 (mAb)
    • 非修飾 (Naked) 單株抗體
      • Avastin (Bevacizumab)
      • Herceptin (Trastuzumab)
    • 結合物 (結合) 單株抗體
      • ADCETRIS (Brentuximab vedotin)
      • Kadcyla (Ado-trastuzumab emtansine/TDM-1)
    • 雙特異性單株抗體
      • Blincyto (Blinatumomab)
    • 其他
  • 治療疫苗
    • Provenge
    • Pediarix/Infanrix
  • 免疫查核點抑制劑
    • CTLA-4抑制劑 (Cytotoxic T-Lymphocyte-Associated Protein-4)
      • Yervoy (Ipilimumab)
    • PD-1/PD-L1抑制劑 (Programmed Death 1/Programmed Death Ligand 1)
      • Opdivo (Nivolumab)
      • Keytruda (pembrolizumab)
  • 其他

第7章 全球癌症免疫療法市場:主要的不同症狀

  • 頭頸椎癌症
  • 肺癌
  • 黑色素瘤
  • 淋巴瘤
  • 白血病
  • 其他

第8章 全球癌症免疫療法市場:各地區

  • 北美
  • 歐洲
  • 亞太地區

第9章 市場趨勢與發展

  • 有利的投資趨勢
  • 標靶治療·聯合治療的登場
  • NSCLC (非小細胞肺癌)·黑色素瘤:癌症免疫療法市場最大部門
  • Bristol-Myers Squibb與Merck & Co:左右癌症免疫療法市場的巨大企業

第10章 癌症免疫療法產業的策略性合作·聯盟的動向

第11章 癌症免疫療法的開發中產品分析

第12章 競爭環境

  • 主要企業的市場佔有率

第13章 主要企業分析

  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Amgen Inc.
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Novartis
  • AstraZeneca Plc
  • Pfizer Inc
  • Eli Lilly and Company

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Immuno-oncology is a unique approach that uses the body's immune system to fight cancer. These therapies activate an individual's immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types. The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.

According to the report "Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022", the global immuno-oncology market is anticipated to cross US$ 100 Billion by 2022. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.

The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).

The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2016, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.

On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Immuno-Oncology: Overview

4. Market Dynamic

  • 4.1 Drivers
    • 4.1.1 Increasing Cancer Incidences
    • 4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
    • 4.1.3 Growing Geriatric Population
    • 4.1.4 High Healthcare Spending in Developed Economies
    • 4.1.5 Strong Pipeline
    • 4.1.6 Increasing Efficacy in a Wide Variety of Indications
    • 4.1.7 urgeoning Approval and Uptake of Immuno-Oncology Products
  • 4.2 Challenges
    • 4.2.1 Patent Expiry of Top-Selling Drugs
    • 4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatment
    • 4.2.3 Sky-High Development Costs of Cancer Immunotherapies
    • 4.2.4 High Cost of Treatment
    • 4.2.5 Lack of Awarenes
  • 4.3 Opportunities
    • 4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunit
    • 4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
    • 4.3.3 CAR-T Therapies: The Future of Cancer Care
    • 4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immuno-Oncology Market Outlook 2022

6. Global Immuno-Oncology Market, by Product Class

  • 6.1 Monoclonal Antibodies (mAbs)
    • 6.1.1 Naked Monoclonal Antibodies
      • 6.1.1.1 Rituxan (Rituximab)
      • 6.1.1.2 Avastin (Bevacizumab)
      • 6.1.1.3 Herceptin (Trastuzumab)
    • 6.1.2 Conjugated Monoclonal Antibodies
      • 6.1.2.1 ADCETRIS (Brentuximab vedotin)
      • 6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
    • 6.1.3 Bispecific Monoclonal Antibodies
      • 6.1.3.1 Blincyto (Blinatumomab)
    • 6.1.4 Others
  • 6.2 Therapeutic Vaccines
    • 6.2.1 Provenge
  • 6.3 Immune Checkpoint Inhibitors
    • 6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
      • 6.3.1.1 Yervoy (Ipilimumab)
    • 6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
      • 6.3.2.1 Opdivo (Nivolumab)
      • 6.3.2.2 Keytruda (Pembrolizumab)
  • 6.4 Others

7. Global Immuno-Oncology Market, By Major Indications

  • 7.1 Head & Neck Cancer
  • 7.2 Lung Cancer
  • 7.3 Melanoma
  • 7.4 Lymphoma
  • 7.5 Leukemia
  • 7.6 Others 118

8. Global Immuno-Oncology Market, By Geography

  • 8.1 North America
  • 8.2 Europe
  • 8.3 Asia-Pacific

9. Trends & Developments

  • 9.1 Lucrative Investment Trend
  • 9.2 Emergence of Targeted and Combination Therapies
  • 9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
  • 9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry

11. Pipeline Analysis of Immuno-Oncology

12. Competitive Landscape

  • 12.1 Share of Major Players

13. Key Players Analysis

  • 13.1 F. Hoffmann-La Roche AG
  • 13.2 Celgene Corporation
  • 13.3 Bristol-Myers Squibb
  • 13.4 Merck & Co., Inc.
  • 13.5 Novartis
  • 13.6 AstraZeneca Plc
  • 13.7 Pfizer Inc
  • 13.8 Eli Lilly and Company
  • 13.9 Johnson & Johnson
  • 13.10 Amgen Inc.

List of Figures:

  • Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
  • Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
  • Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
  • Figure 4-4: Expected Combination Regimen Launches in Oncology
  • Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2016
  • Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2022
  • Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2016-2022
  • Figure 6-4: Global - Rituxan Market (Billion US$), 2012-2016
  • Figure 6-5: Global - Avastin Market (Billion US$), 2012-2016
  • Figure 6-6: Global - Herceptin Market (Billion US$), 2012-2016
  • Figure 6-7: Global - ADCETRIS Market (Million US$), 2012-2016
  • Figure 6-8: Global - Kadcyla Market (Million US$), 2013-2016
  • Figure 6-9: Global - Blincyto Market (Million US$), 2014-2016
  • Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), 2016-2022
  • Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Billion US$), 2016-2022
  • Figure 6-12: Global - Provenge Market (Million US$), 2012-2016
  • Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
  • Figure 6-14: Global - Yervoy Market (Million US$), 2012-2016
  • Figure 6-15: Global - Opdivo Market (Million US$), 2014-2016
  • Figure 6-16: Global - Keytruda Market (Million US$), 2014-2016
  • Figure 6-17: Global - Others Market (Billion US$), 2016-2022
  • Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2016
  • Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2022
  • Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2016-2022
  • Figure 7-4: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-5: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-6: Global - Lung Cancer Market (Billion US$), 2016-2022
  • Figure 7-7: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-8: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-9: Global - Melanoma Market (Billion US$), 2016-2022
  • Figure 7-10: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-11: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-12: Global - Lymphoma Market (Billion US$), 2016-2022
  • Figure 7-13: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-14: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-15: Global - Leukemia Market (Billion US$), 2016-2022
  • Figure 7-16: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-17: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-18: Global - Other Cancer Market (Billion US$), 2016-2022
  • Figure 7-19: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-20: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 8-1: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2016
  • Figure 8-2: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2022
  • Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2016-2022
  • Figure 9-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016
  • Figure 9-2: Major Investors in Immuno-Oncology Market (2015-2016)
  • Figure 9-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
  • Figure 11-1: Global - Immuno-Oncology Pipeline Analysis by Product Type (%), 2016
  • Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2016
  • Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2015
  • Figure 13-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016
  • Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016
  • Figure 13-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016
  • Figure 13-4: Celgene Corporation - Sales by Products (%), 2016
  • Figure 13-5: Bristol Myers Squibb - Revenue by Business Segments (%), 2016
  • Figure 13-6: Bristol Myers Squibb - Revenue by Geography (%), 2016
  • Figure 13-7: Merck & Co., Inc. - Revenue by Business Segments (%), 2016
  • Figure 13-8: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016
  • Figure 13-9: Merck & Co., Inc. - Revenue by Geography (%), 2016
  • Figure 13-10: Novartis - Sales by Business Segments (%), 2016
  • Figure 13-11: Novartis - Innovative Medicines Division Sales by Segments (%), 2016
  • Figure 13-12: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016
  • Figure 13-13: Novartis - Sales by Geography (%), 2016
  • Figure 13-14: AstraZeneca Plc - Revenue by Business Segments (%), 2016
  • Figure 13-15: AstraZeneca Plc - Revenue by Geography (%), 2016
  • Figure 13-16: Pfizer Inc - Revenue by Business Segments (%), 2016
  • Figure 13-17: Pfizer Inc - Revenue by Geography (%), 2016
  • Figure 13-18: Eli Lilly and Company - Revenue by Business Segments (%), 2016
  • Figure 13-19: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segments (%), 2016
  • Figure 13-20: Eli Lilly and Company - Revenue by Geography (%), 2016
  • Figure 13-21: Johnson & Johnson - Sales by Business Segments (%), 2016
  • Figure 13-22: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016
  • Figure 13-23: Johnson & Johnson - Sales by Geography (%), 2016
  • Figure 13-24: Amgen Inc. - Sales by Product (%), 2016
  • Figure 13-25: Amgen Inc. - Sales by Geography (%), 2016

List of Tables:

  • Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
  • Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
  • Table 6-1: Ongoing Trials for Rituxan
  • Table 6-2: Ongoing Trials for Avastin
  • Table 6-3: Ongoing Trials for Herceptin
  • Table 6-4: Ongoing Trials for ADCETRIS
  • Table 6-5: Ongoing Trials for Kadcyla
  • Table 6-6: Ongoing Trials for Blincyto
  • Table 6-7: Ongoing Trials for Other Monoclonal Antibodies
  • Table 6-8: Ongoing Trials for Provenge
  • Table 6-9: Ongoing Trials for Yervoy
  • Table 6-10: Ongoing Trials for Opdivo
  • Table 6-11: Ongoing Trials for Keytruda
  • Table 6-12: Ongoing Trials for Other Immuno-Oncology Products
  • Table 7-1: Global - Oncology Incidence by Geography ('000), 2015 & 2020
  • Table 9-1: Immuno-Oncology Companies that Received Venture Capital Investments
  • Table 9-2: Selected Immuno-Oncology and/or Targeted Therapy Combinations
  • Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
  • Table 11-1: Active Immuno-Oncology Programs
  • Table 11-2: Global - Immuno-Oncology Product Pipeline
  • Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016
  • Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products
  • Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline
  • Table 13-4: Celgene Corporation - Key Financials (Million US$), 2014-2016
  • Table 13-5: Celgene Corporation - Commercialized Immuno-Oncology Products
  • Table 13-6: Celgene Corporation - Product Pipeline
  • Table 13-7: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016
  • Table 13-8: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
  • Table 13-9: Bristol Myers Squibb - Product Pipeline
  • Table 13-10: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016
  • Table 13-11: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
  • Table 13-12: Merck & Co., Inc. - Product Pipeline
  • Table 13-13: Novartis - Key Financials (Billion US$), 2014-2016
  • Table 13-14: Novartis - Commercialized Immuno-Oncology Products
  • Table 13-15: Novartis - Product Pipeline
  • Table 13-16: AstraZeneca Plc - Key Financials (Million US$), 2014-2016
  • Table 13-17: AstraZeneca Plc - Commercialized Immuno-Oncology Products
  • Table 13-18: AstraZeneca Plc - Product Pipeline
  • Table 13-19: Pfizer Inc - Key Financials (Billion US$), 2014-2016
  • Table 13-20: Pfizer Inc - Commercialized Immuno-Oncology Products
  • Table 13-21: Pfizer Inc - Product Pipeline
  • Table 13-22: Eli Lilly and Company - Key Financials (Million US$), 2014-2016
  • Table 13-23: Eli Lilly and Company - Commercialized Immuno-Oncology Products
  • Table 13-24: Eli Lilly and Company - Product Pipeline
  • Table 13-25: Johnson & Johnson - Key Financials (Billion US$), 2014-2016
  • Table 13-26: Johnson & Johnson - Commercialized Immuno-Oncology Products
  • Table 13-27: Johnson & Johnson - Product Pipeline
  • Table 13-28: Amgen Inc. - Key Financials (Billion US$), 2014-2016
  • Table 13-29: Amgen Inc. - Commercialized Immuno-Oncology Products
  • Table 13-30: Amgen Inc. - Product Pipeline
Back to Top